Target Found for Kidney Cancer Drug Resistance
Researchers identified a protein that may help renal cell carcinoma patients overcome resistance to the drug sunitinib.
Updated on Sept. 30, 2026 in Cancer
Scientists have linked increased expression of the protein NSUN5 to sunitinib resistance in renal cell carcinoma. This finding suggests a new potential therapeutic target for patients whose tumors no longer respond to standard treatment.
Why it matters
Understanding the mechanisms behind treatment resistance is essential for improving prognosis in advanced kidney cancer. This discovery highlights a pathway that drives oncogenic signaling when current therapies fail.
In a preclinical study using patient-derived xenografts, researchers observed that blocking NSUN5 reduced tumor growth. This experimental finding indicates that NSUN5 expression levels correlate with clinical prognosis for patients receiving sunitinib.
The players
NSUN5
A protein identified as a regulator of mRNA modification and a key factor in cancer drug resistance.
YBX1
An m5C reader protein that facilitates the stabilization of cancer-promoting transcripts.
Sunitinib
A standard-of-care medication used to treat renal cell carcinoma that can lose efficacy over time.
The details
NSUN5 normally catalyzes m5C modifications on Fibronectin 1 mRNA, which increases the stability of those transcripts and aids recognition by the YBX1 protein. This process triggers the PI3K/AKT signaling pathway, fueling tumor survival and resistance to sunitinib. Researchers successfully identified a small-molecular inhibitor that lowers m5C levels, effectively disrupting this resistance mechanism in laboratory models.
Timeline
September 30, 2026: Findings were published online.
Health Landscape
This study identifies a novel regulatory node within the well-characterized PI3K/AKT signaling pathway. It represents a shift toward targeting the underlying molecular machinery that allows renal cell carcinoma to circumvent existing pharmacologic interventions.
This is an early-stage laboratory finding and does not change clinical practice at this time. If you or a loved one are managing renal cell carcinoma and have concerns about treatment resistance, discuss emerging clinical trial options with your oncologist.
The takeaway
The discovery of NSUN5 provides a vital target for future research into overcoming drug resistance in kidney cancer. Patients and caregivers should continue to monitor clinical trial databases for new therapeutic developments as this research progresses.
Further reading
For more information on the latest developments in oncology research, visit Cancer.
Source note: This article includes information reported by Nature.
